FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019013083> ?p ?o ?g. }

• W2019013083 endingPage "e96187" @default.
• W2019013083 startingPage "e96187" @default.
• W2019013083 abstract "Objective Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study’s primary objective was to determine whether abacavir/lamivudine + atazanavir (ABC/3TC+ATV) was virologically non-inferior to tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC+ATV/r) over 24 weeks in a population of virologically suppressed, HIV-1 infected patients. Design This open-label, multicenter, non-inferiority study enrolled antiretroviral experienced, HIV-infected adults currently receiving a regimen of TDF/FTC+ATV/r for ≥6 months with no history of virologic failure and whose HIV-1 RNA had been ≤75 copies/mL on 2 consecutive measurements including screening. Patients were randomized 1∶2 to continue current treatment or simplify to ABC/3TC+ATV. Methods The primary endpoint was the proportion of patients with HIV-RNA<50 copies/mL at Week 24 by the Time to Loss of Virologic Response (TLOVR) algorithm. Secondary endpoints included alternative measures of efficacy, adverse events (AEs), and fasting lipids. Exploratory endpoints included inflammatory, coagulation, bone, and renal biomarkers. Results After 24 weeks, ABC/3TC+ATV (n = 199) was non-inferior to TDF/FTC+ATV/r (n = 97) by both the primary analysis (87% in both groups) and all secondary efficacy analyses. Rates of grade 2–4 AEs were similar between the two groups (40% vs 37%, respectively), but an excess of hyperbilirubinemia made the rate of grade 3–4 laboratory abnormalities higher in the TDF/FTC+ATV/r group (30%) compared with the ABC/3TC+ATV group (13%). Lipid levels were stable except for HDL cholesterol, which increased significantly in the ABC/3TC+ATV group. Bone and renal biomarkers improved significantly between baseline and Week 24 in patients taking ABC/3TC+ATV, and the difference between groups was significant at Week 24. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups. Conclusions After 24 weeks, simplification to ABC/3TC+ATV from TDF/FTC+ATV/r maintained viral suppression was well-tolerated, and led to improvements in bone and renal biomarkers and HDL cholesterol. Trial Registration ClinicalTrials.gov NCT01102972 GlaxoSmithKline Clinical Study Register #113734" @default.
• W2019013083 created "2016-06-24" @default.
• W2019013083 creator A5020883910 @default.
• W2019013083 creator A5021428464 @default.
• W2019013083 creator A5042040728 @default.
• W2019013083 creator A5043793286 @default.
• W2019013083 creator A5053516032 @default.
• W2019013083 creator A5060710888 @default.
• W2019013083 creator A5060800198 @default.
• W2019013083 creator A5069581471 @default.
• W2019013083 creator A5076360870 @default.
• W2019013083 creator A5079973774 @default.
• W2019013083 date "2014-05-13" @default.
• W2019013083 modified "2023-09-25" @default.
• W2019013083 title "Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial" @default.
• W2019013083 cites W1962312697 @default.
• W2019013083 cites W1966288369 @default.
• W2019013083 cites W1967448985 @default.
• W2019013083 cites W1970354828 @default.
• W2019013083 cites W1978257549 @default.
• W2019013083 cites W1980690358 @default.
• W2019013083 cites W1988101744 @default.
• W2019013083 cites W1988633664 @default.
• W2019013083 cites W1996364592 @default.
• W2019013083 cites W2006498349 @default.
• W2019013083 cites W2013975989 @default.
• W2019013083 cites W2017230984 @default.
• W2019013083 cites W2036223783 @default.
• W2019013083 cites W2047513859 @default.
• W2019013083 cites W2052586853 @default.
• W2019013083 cites W2054497120 @default.
• W2019013083 cites W2055864845 @default.
• W2019013083 cites W2056779298 @default.
• W2019013083 cites W2064341017 @default.
• W2019013083 cites W2076420181 @default.
• W2019013083 cites W2083692806 @default.
• W2019013083 cites W2115919377 @default.
• W2019013083 cites W2121850733 @default.
• W2019013083 cites W2144095981 @default.
• W2019013083 cites W2144658061 @default.
• W2019013083 cites W2147357250 @default.
• W2019013083 cites W2148092884 @default.
• W2019013083 cites W2166409471 @default.
• W2019013083 cites W4238251256 @default.
• W2019013083 doi "https://doi.org/10.1371/journal.pone.0096187" @default.
• W2019013083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4019479" @default.
• W2019013083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24825167" @default.
• W2019013083 hasPublicationYear "2014" @default.
• W2019013083 type Work @default.
• W2019013083 sameAs 2019013083 @default.
• W2019013083 citedByCount "22" @default.
• W2019013083 countsByYear W20190130832015 @default.
• W2019013083 countsByYear W20190130832016 @default.
• W2019013083 countsByYear W20190130832017 @default.
• W2019013083 countsByYear W20190130832018 @default.
• W2019013083 countsByYear W20190130832019 @default.
• W2019013083 crossrefType "journal-article" @default.
• W2019013083 hasAuthorship W2019013083A5020883910 @default.
• W2019013083 hasAuthorship W2019013083A5021428464 @default.
• W2019013083 hasAuthorship W2019013083A5042040728 @default.
• W2019013083 hasAuthorship W2019013083A5043793286 @default.
• W2019013083 hasAuthorship W2019013083A5053516032 @default.
• W2019013083 hasAuthorship W2019013083A5060710888 @default.
• W2019013083 hasAuthorship W2019013083A5060800198 @default.
• W2019013083 hasAuthorship W2019013083A5069581471 @default.
• W2019013083 hasAuthorship W2019013083A5076360870 @default.
• W2019013083 hasAuthorship W2019013083A5079973774 @default.
• W2019013083 hasBestOaLocation W20190130831 @default.
• W2019013083 hasConcept C126322002 @default.
• W2019013083 hasConcept C142462285 @default.
• W2019013083 hasConcept C159047783 @default.
• W2019013083 hasConcept C168563851 @default.
• W2019013083 hasConcept C197934379 @default.
• W2019013083 hasConcept C203092338 @default.
• W2019013083 hasConcept C2522874641 @default.
• W2019013083 hasConcept C2777869810 @default.
• W2019013083 hasConcept C2778414717 @default.
• W2019013083 hasConcept C2779298103 @default.
• W2019013083 hasConcept C2779465607 @default.
• W2019013083 hasConcept C2779778239 @default.
• W2019013083 hasConcept C2780593183 @default.
• W2019013083 hasConcept C2781413609 @default.
• W2019013083 hasConcept C2781432083 @default.
• W2019013083 hasConcept C2908647359 @default.
• W2019013083 hasConcept C2993143319 @default.
• W2019013083 hasConcept C3013748606 @default.
• W2019013083 hasConcept C71924100 @default.
• W2019013083 hasConcept C90924648 @default.
• W2019013083 hasConcept C99454951 @default.
• W2019013083 hasConceptScore W2019013083C126322002 @default.
• W2019013083 hasConceptScore W2019013083C142462285 @default.
• W2019013083 hasConceptScore W2019013083C159047783 @default.
• W2019013083 hasConceptScore W2019013083C168563851 @default.
• W2019013083 hasConceptScore W2019013083C197934379 @default.
• W2019013083 hasConceptScore W2019013083C203092338 @default.
• W2019013083 hasConceptScore W2019013083C2522874641 @default.
• W2019013083 hasConceptScore W2019013083C2777869810 @default.
• W2019013083 hasConceptScore W2019013083C2778414717 @default.

• next